Baseline and follow-up characteristics of the complete cardiac amyloidosis cohort
| Variable . | Baseline . | Follow-up . | P value . |
|---|---|---|---|
| (n = 103) . | (n = 103) . | ||
| Clinical parameters | |||
| Age, years | 75.0 (68.0–79.0) | 77.0 (70.0–81.0) | <0.001 |
| Sex, male gender, n | 82 (79.6) | 82 (79.6) | 1.000 |
| NYHA functional class ≥ III, n | 36 (35.0) | 25 (24.3) | 0.054 |
| 6-min walk test, m | 400 (296–480) | 402 (323–486) | 0.858 |
| N-terminal pro brain natriuretic peptide, pg/mL | 1917 (787–3542) | 2222 (810–3502) | 0.400 |
| Troponin T, ng/mL | 0.043 (0.029–0.065) | 0.051 (0.028–0.071) | 0.093 |
| eGFR, mL/min/1.73m2 | 56.5 (42.4–75.0) | 54.0 (43.0–68.7) | 0.019 |
| Cardiac magnetic resonance imaging parameters | |||
| Myocardial native T1 time, ms | 1099 (1057–1139) | 1107 (1077–1144) | 0.006 |
| Individual change of myocardial T1 time, % | +12.0 (−17.5 to +36.3) | n.a | |
| Extracellular volume, % | 48.0 (40.0–55.3) | 50.5 (43.1–59.5) | <0.001 |
| Individual change of extracellular volume, % | +3.5 (−1.9 to +6.9) | n.a | |
| Interventricular septum, mm | 18.0 (15.0–21.0) | 18.4 (16.0–22.0) | 0.695 |
| Left ventricular mass, g | 194 (154–229) | 195 (150–231) | 0.449 |
| Left atrial area, cm2 | 31.0 (26.0–37.0) | 32.0 (28.0–36.0) | 0.591 |
| Right atrial area, cm2 | 30.0 (25.0–36.0) | 30.0 (26.8–35.0) | 0.241 |
| Left ventricular global longitudinal strain, % | −12.6 (−15.3 to −10.1) | −12.3 (−15.4 to −9.5) | 0.348 |
| Left ventricular ejection fraction, % | 56.0 (47.0–62.0) | 50.6 (45.0–60.0) | 0.009 |
| Left ventricular cardiac output, L/min | 5.7 (4.9–6.5) | 5.8 (4.9–6.4) | 0.829 |
| Left ventricular end-diastolic volume, mL | 159 (139–189) | 166 (150–205) | <0.001 |
| Right ventricular ejection fraction, % | 49.0 (41.0–58.0) | 45.9 (39.0–53.0) | <0.001 |
| Right ventricular cardiac output, L/min | 5.3 (4.5–6.4) | 5.3 (4.4–6.3) | 0.745 |
| Right ventricular end-diastolic volume, mL | 171 (142–191) | 177 (154–209) | <0.001 |
| Pulmonary artery, mm | 28.0 (25.0–31.0) | 28.0 (25.0–31.0) | 0.786 |
| Pleural effusion, n | 28 (27.2) | 35 (34.0) | 0.189 |
| Pericardial effusion, n | 43 (41.7) | 44 (42.7) | 1.000 |
| Variable . | Baseline . | Follow-up . | P value . |
|---|---|---|---|
| (n = 103) . | (n = 103) . | ||
| Clinical parameters | |||
| Age, years | 75.0 (68.0–79.0) | 77.0 (70.0–81.0) | <0.001 |
| Sex, male gender, n | 82 (79.6) | 82 (79.6) | 1.000 |
| NYHA functional class ≥ III, n | 36 (35.0) | 25 (24.3) | 0.054 |
| 6-min walk test, m | 400 (296–480) | 402 (323–486) | 0.858 |
| N-terminal pro brain natriuretic peptide, pg/mL | 1917 (787–3542) | 2222 (810–3502) | 0.400 |
| Troponin T, ng/mL | 0.043 (0.029–0.065) | 0.051 (0.028–0.071) | 0.093 |
| eGFR, mL/min/1.73m2 | 56.5 (42.4–75.0) | 54.0 (43.0–68.7) | 0.019 |
| Cardiac magnetic resonance imaging parameters | |||
| Myocardial native T1 time, ms | 1099 (1057–1139) | 1107 (1077–1144) | 0.006 |
| Individual change of myocardial T1 time, % | +12.0 (−17.5 to +36.3) | n.a | |
| Extracellular volume, % | 48.0 (40.0–55.3) | 50.5 (43.1–59.5) | <0.001 |
| Individual change of extracellular volume, % | +3.5 (−1.9 to +6.9) | n.a | |
| Interventricular septum, mm | 18.0 (15.0–21.0) | 18.4 (16.0–22.0) | 0.695 |
| Left ventricular mass, g | 194 (154–229) | 195 (150–231) | 0.449 |
| Left atrial area, cm2 | 31.0 (26.0–37.0) | 32.0 (28.0–36.0) | 0.591 |
| Right atrial area, cm2 | 30.0 (25.0–36.0) | 30.0 (26.8–35.0) | 0.241 |
| Left ventricular global longitudinal strain, % | −12.6 (−15.3 to −10.1) | −12.3 (−15.4 to −9.5) | 0.348 |
| Left ventricular ejection fraction, % | 56.0 (47.0–62.0) | 50.6 (45.0–60.0) | 0.009 |
| Left ventricular cardiac output, L/min | 5.7 (4.9–6.5) | 5.8 (4.9–6.4) | 0.829 |
| Left ventricular end-diastolic volume, mL | 159 (139–189) | 166 (150–205) | <0.001 |
| Right ventricular ejection fraction, % | 49.0 (41.0–58.0) | 45.9 (39.0–53.0) | <0.001 |
| Right ventricular cardiac output, L/min | 5.3 (4.5–6.4) | 5.3 (4.4–6.3) | 0.745 |
| Right ventricular end-diastolic volume, mL | 171 (142–191) | 177 (154–209) | <0.001 |
| Pulmonary artery, mm | 28.0 (25.0–31.0) | 28.0 (25.0–31.0) | 0.786 |
| Pleural effusion, n | 28 (27.2) | 35 (34.0) | 0.189 |
| Pericardial effusion, n | 43 (41.7) | 44 (42.7) | 1.000 |
NYHA, New York Heart Association; eGFR, estimated glomerular filtration rate; n.a, not applicable. Numbers in brackets are % for dichotomous and IQR for continuous variables.
Magnetic resonance imaging. T0 was date of follow-up CMR.
Baseline and follow-up characteristics of the complete cardiac amyloidosis cohort
| Variable . | Baseline . | Follow-up . | P value . |
|---|---|---|---|
| (n = 103) . | (n = 103) . | ||
| Clinical parameters | |||
| Age, years | 75.0 (68.0–79.0) | 77.0 (70.0–81.0) | <0.001 |
| Sex, male gender, n | 82 (79.6) | 82 (79.6) | 1.000 |
| NYHA functional class ≥ III, n | 36 (35.0) | 25 (24.3) | 0.054 |
| 6-min walk test, m | 400 (296–480) | 402 (323–486) | 0.858 |
| N-terminal pro brain natriuretic peptide, pg/mL | 1917 (787–3542) | 2222 (810–3502) | 0.400 |
| Troponin T, ng/mL | 0.043 (0.029–0.065) | 0.051 (0.028–0.071) | 0.093 |
| eGFR, mL/min/1.73m2 | 56.5 (42.4–75.0) | 54.0 (43.0–68.7) | 0.019 |
| Cardiac magnetic resonance imaging parameters | |||
| Myocardial native T1 time, ms | 1099 (1057–1139) | 1107 (1077–1144) | 0.006 |
| Individual change of myocardial T1 time, % | +12.0 (−17.5 to +36.3) | n.a | |
| Extracellular volume, % | 48.0 (40.0–55.3) | 50.5 (43.1–59.5) | <0.001 |
| Individual change of extracellular volume, % | +3.5 (−1.9 to +6.9) | n.a | |
| Interventricular septum, mm | 18.0 (15.0–21.0) | 18.4 (16.0–22.0) | 0.695 |
| Left ventricular mass, g | 194 (154–229) | 195 (150–231) | 0.449 |
| Left atrial area, cm2 | 31.0 (26.0–37.0) | 32.0 (28.0–36.0) | 0.591 |
| Right atrial area, cm2 | 30.0 (25.0–36.0) | 30.0 (26.8–35.0) | 0.241 |
| Left ventricular global longitudinal strain, % | −12.6 (−15.3 to −10.1) | −12.3 (−15.4 to −9.5) | 0.348 |
| Left ventricular ejection fraction, % | 56.0 (47.0–62.0) | 50.6 (45.0–60.0) | 0.009 |
| Left ventricular cardiac output, L/min | 5.7 (4.9–6.5) | 5.8 (4.9–6.4) | 0.829 |
| Left ventricular end-diastolic volume, mL | 159 (139–189) | 166 (150–205) | <0.001 |
| Right ventricular ejection fraction, % | 49.0 (41.0–58.0) | 45.9 (39.0–53.0) | <0.001 |
| Right ventricular cardiac output, L/min | 5.3 (4.5–6.4) | 5.3 (4.4–6.3) | 0.745 |
| Right ventricular end-diastolic volume, mL | 171 (142–191) | 177 (154–209) | <0.001 |
| Pulmonary artery, mm | 28.0 (25.0–31.0) | 28.0 (25.0–31.0) | 0.786 |
| Pleural effusion, n | 28 (27.2) | 35 (34.0) | 0.189 |
| Pericardial effusion, n | 43 (41.7) | 44 (42.7) | 1.000 |
| Variable . | Baseline . | Follow-up . | P value . |
|---|---|---|---|
| (n = 103) . | (n = 103) . | ||
| Clinical parameters | |||
| Age, years | 75.0 (68.0–79.0) | 77.0 (70.0–81.0) | <0.001 |
| Sex, male gender, n | 82 (79.6) | 82 (79.6) | 1.000 |
| NYHA functional class ≥ III, n | 36 (35.0) | 25 (24.3) | 0.054 |
| 6-min walk test, m | 400 (296–480) | 402 (323–486) | 0.858 |
| N-terminal pro brain natriuretic peptide, pg/mL | 1917 (787–3542) | 2222 (810–3502) | 0.400 |
| Troponin T, ng/mL | 0.043 (0.029–0.065) | 0.051 (0.028–0.071) | 0.093 |
| eGFR, mL/min/1.73m2 | 56.5 (42.4–75.0) | 54.0 (43.0–68.7) | 0.019 |
| Cardiac magnetic resonance imaging parameters | |||
| Myocardial native T1 time, ms | 1099 (1057–1139) | 1107 (1077–1144) | 0.006 |
| Individual change of myocardial T1 time, % | +12.0 (−17.5 to +36.3) | n.a | |
| Extracellular volume, % | 48.0 (40.0–55.3) | 50.5 (43.1–59.5) | <0.001 |
| Individual change of extracellular volume, % | +3.5 (−1.9 to +6.9) | n.a | |
| Interventricular septum, mm | 18.0 (15.0–21.0) | 18.4 (16.0–22.0) | 0.695 |
| Left ventricular mass, g | 194 (154–229) | 195 (150–231) | 0.449 |
| Left atrial area, cm2 | 31.0 (26.0–37.0) | 32.0 (28.0–36.0) | 0.591 |
| Right atrial area, cm2 | 30.0 (25.0–36.0) | 30.0 (26.8–35.0) | 0.241 |
| Left ventricular global longitudinal strain, % | −12.6 (−15.3 to −10.1) | −12.3 (−15.4 to −9.5) | 0.348 |
| Left ventricular ejection fraction, % | 56.0 (47.0–62.0) | 50.6 (45.0–60.0) | 0.009 |
| Left ventricular cardiac output, L/min | 5.7 (4.9–6.5) | 5.8 (4.9–6.4) | 0.829 |
| Left ventricular end-diastolic volume, mL | 159 (139–189) | 166 (150–205) | <0.001 |
| Right ventricular ejection fraction, % | 49.0 (41.0–58.0) | 45.9 (39.0–53.0) | <0.001 |
| Right ventricular cardiac output, L/min | 5.3 (4.5–6.4) | 5.3 (4.4–6.3) | 0.745 |
| Right ventricular end-diastolic volume, mL | 171 (142–191) | 177 (154–209) | <0.001 |
| Pulmonary artery, mm | 28.0 (25.0–31.0) | 28.0 (25.0–31.0) | 0.786 |
| Pleural effusion, n | 28 (27.2) | 35 (34.0) | 0.189 |
| Pericardial effusion, n | 43 (41.7) | 44 (42.7) | 1.000 |
NYHA, New York Heart Association; eGFR, estimated glomerular filtration rate; n.a, not applicable. Numbers in brackets are % for dichotomous and IQR for continuous variables.
Magnetic resonance imaging. T0 was date of follow-up CMR.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
